Business Context and Reporting Period
Company: United Therapeutics Corporation (UTHR)
Filing Type: Form 8-K (Current Report)
Date of Report: September 8, 2026
Event: Entry into a Material Definitive Agreement (Accelerated Share Repurchase).
Key Financial Metrics
This filing reports a specific capital allocation transaction rather than periodic financial performance. The filing text does not provide revenue, profit, cash flow, margins, or debt figures for the reporting period.
- Transaction Value: Approximately $477.6 million.
- Upfront Payment: Approximately $477.6 million to be paid to Citibank, N.A. on or around September 10, 2026.
- Initial Share Delivery: Approximately 719,376 shares of Common Stock (representing ~75% of the total expected repurchase).
- Settlement Timing: Expected completion in the fourth quarter of 2026.
Material Changes
The primary material change is the execution of an Accelerated Share Repurchase (ASR) Agreement with Citibank, N.A. under the Company's previously announced Share Repurchase Program. This represents a significant deployment of cash reserves to reduce outstanding share count.
Outlook, Risks, and Unusual Items
Management Commentary: The Company is proceeding with a significant buyback to return value to shareholders. The final number of shares repurchased will be determined based on the average daily volume-weighted average price (VWAP) of the Common Stock during the term of the agreement, less a discount.
Contingencies and Risks:
- Settlement Variability: At final settlement, the Company may receive additional shares or, in limited circumstances, be required to make a cash payment to Citi or deliver shares to Citi.
- Timing: Final settlement is contingent on market conditions and the terms of the agreement, expected in Q4 2026.
Investor Verification Checklist
- Verify the impact of the $477.6 million upfront cash outflow on the Company's current liquidity position.
- Monitor the final settlement in Q4 2026 to determine the total number of shares repurchased and any potential cash adjustments.
- Review the Company's remaining authorization under the Share Repurchase Program post-transaction.
- Confirm the specific discount mechanism and VWAP calculation terms referenced in the master confirmation filed as Exhibit 10.1.